The IAS–USA 30th Annual Update on HIV Management in Chicago, Illinois

The IAS–USA 30th Annual Update on HIV Management in Chicago, Illinois

Registration Details

  • Virtual Registration: $35.00 (USD)
  • Virtual Registration ends: Thursday, December 8, 2022
  • Virtual Fellows: $25.00 (USD)
  • Virtual Fellows ends: Thursday, December 8, 2022

Faculty

Roger J. Bedimo, MD, MS
University of Texas Southwestern Medical Center
Constance A. Benson, MD
University of California San Diego
Jill Blumenthal, MD, MAS
University of California San Diego
Michael S. Saag, MD
University of Alabama at Birmingham
Paul A. Volberding, MD
University of California San Francisco

December 8, 2022

8:00 AM - 1:30 PM PT

List of Topics

  • Broadly Neutralizing Antibodies: Where Are We Going?
  • In Case You Missed It: Updates from IAS and Recent Literature
  • Antiretroviral Therapy Case-Based Panel Discussion
  • The Effect of the Pandemic on Ending the HIV Epidemic Initiative
  • Providing Gender Affirming Care
  • Anal Cancer Screening: What Now?

Last Modified: Aug 2, 2022 @ 9:08 AM

Program Description

This live virtual course will provide the latest updates on HIV research, antiretroviral therapy, the state of the Ending the HIV Epidemic Initiative, providing gender affirming care in your clinic, and what to do with anal human papillomavirus screening results.

Assessment of Needs

Rapid advances in HIV disease management and COVID-19 information require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and COVID-19. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Describe the current status of broadly neutralizing antibodies (bNABs) and the future direction of  bNABs in HIV treatment
  • Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data from recent HIV meetings and literature, including research on new and investigational antiretroviral drugs
  • Describe the current status of the Ending the HIV Epidemic
  • Provide gender affirming care
  • Implement anal cancer screening

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

BRONZE SUPPORTER

Theratechnologies, Inc.

Frequently Asked Questions

View our list of FAQs about attending an activity.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.